

## **Press Release**

## STADA subsidiary supports victims of Balkan flood

## Serbian STADA subsidiary Hemofarm donates goods valued at Euro 380,000 for quick aid in the flooded areas of Serbia and Bosnia

Bad Vilbel, May 20, 2014 – As a result of the most severe rainfall in more than 120 years, which has lead to drastic flooding in large parts of Serbia and Bosnia, STADA's Serbian subsidiary Hemofarm has sent relief supplies valued at Euro 380,000 to the affected areas. In addition, the company's plant fire brigade and numerous Hemofarm employees have offered their services to assist in disaster control.

"We have already provided aid for many national and international catastrophes, whether in the form of monetary donations or relief supplies such as medicines. As a globally active health company that has committed itself to people's well being, it is a matter of course for us", says Hartmut Retzlaff, Chairman of the Executive Board of STADA Arzneimittel AG. The government of Serbia has declared the situation to be the worst natural disaster ever to hit the country and has requested international help. Bosnian authorities have also expressed the need for help. "We are happy to answer this call for help and hope that our donations will help improve the situation for the affected people in need", adds Retzlaff.

The Serbien government has expressed its gratitude for the quick help offered by Hemofarm – the market leader in Serbia's health care market. Both sides continue to cooperate closely with regard to the next steps.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels Chairman of the Supervisory Board: Dr. Martin Abend



## About STADA Arzneimittel AG:

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. STADA consistently focuses on a multi-pillar strategy of generics and branded products (OTC) with an increasingly international market orientation. The Group is the only independent generics producer in Germany. Worldwide, STADA is represented in 29 countries with 47 subsidiaries. Branded products such as Grippostad, Ladival and Mobilat are among the highest selling in their product category in Germany. In financial year 2013, STADA achieved Group sales of Euro 2,014.4 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of Euro 415.2 million and adjusted net income of Euro 160.6 million. As of December 31, 2013, STADA employed 9,825 people worldwide.

For more information, please contact:

STADA Arzneimittel AG Media Relations Stadastraße 2-18 61118 Bad Vilbel Germany phone: +49(0) 6101 603-165 fax: +49(0) 6101 603-506 e-mail: <u>press@stada.de</u> web: <u>www.stada.de</u>

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Matthias Wiedenfels Chairman of the Supervisory Board: Dr. Martin Abend